Details of the Drug Combinations | DrugMAP

General Information of This Drug (ID: DM5BL4C)

Drug Name

Veltuzumab DM5BL4C

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Systemic lupus erythematosus	4A40.0	Phase 2	[1]
Thrombocytopenia	3B64	Phase 1/2	[3]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Veltuzumab + Epratuzumab Y-90	DCSVVIU	Epratuzumab Y-90	Diffuse large B-cell lymphoma	[4]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8268).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014 Nov;99(11):1738-45.